COMP <GO>
FDMT vs ATTO // EV/EBITDA & P/E VALUATION
4D Molecular Therapeutics Inc. (NASDAQ) VS. Attovia Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: FDMT 2
— ATTO 0
■ METRIC PARITY
LAST: $12.78 (-1.16%) • MKT CAP: $706.0M
valuation
—
LAST: $15.27 (-3.35%) • MKT CAP: $697.1M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (FDMT VS. ATTO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | FDMT | ATTO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -28.30% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -15.53% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.17 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.1 | 43.4 | +0.76 | FDMT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $706.0M | $697.1M | $8.9M | FDMT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | FDMT REV | ATTO REV | FDMT GROSS % | ATTO GROSS % | FDMT FCF | ATTO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $85.2M | $0 | — | — | -$109.6M | — |
| FY 2024 | $37.0K | — | — | — | -$138.4M | — |
| FY 2023 | $20.7M | — | — | — | -$75.8M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
FDMT // BETA —
ATTO // BETA —